Breast Cancer - Biotech, Pharma and Life Science Channel
Breast cancer in the UK is diagnosed in nearly 46,000 people each year, with just over 12,000 dying from breast cancer each year in he UK. There are several risk factors for developing breast cancer including age and a family history of the disease (BRAC2 gene mutation).
The type of cancer determines the treatment options, which have improved over the last decade or so;
Chemotherapy uses cytotoxic drugs to destroy breast cancer cells. It is known as a systemic treatment because the whole body is exposed to the drugs. This may be used in addition to surgery and/or radiotherapy, and it is usually given after surgery and before radiotherapy (adjuvant chemotherapy) or before surgery (neo-adjuvant chemotherapy or primary chemotherapy).
Hormone therapy may be used if your breast cancer is hormone receptor positive. Oestrogen receptor positive cancers make up around 75 per cent of breast cancers in post-menopausal women and around 50 to 60 per cent in pre-menopausal women. A hormone receptor test is now routinely carried out on tissue taken during a biopsy or after the operation to remove the breast cancer.
Radiotherapy uses high energy x-rays to destroy cancer cells, either before or after surgery. Surgery is usually the first treatment for breast cancer; either breast conserving surgery (lumpectomy or wide local excision) or a total mastectomy. Lymph nodes in the axilla be also be removed. Targeted therapies such as Herceptin (trastuzumab) are becoming more widely used, as they target the cancer cells directly, and there are clinical trials for many at the moment.
Source; Adapted from Breast Cancer Care
Add the Breast Cancer News Channel to your RSS reader;
Follow the Breast Cancer Twitter Feed;
Follow the Breast Cancer Facebook page;
PubMed Articles
The influence of genetic polymorphisms in MDR1 gene on breast cancer risk factors in Chinese.
Breast cancer (BC) is the most common cancer among women in the world. The human multidrug resistance 1 gene (MDR1) is potentially an important gene influencing the susceptibility to breast cancer. Th...
Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer.
Synuclein gamma (SNCG), previously identified as breast cancer-specific gene 1, is highly expressed in malignant cells but not in normal epithelium. Studies have demonstrated that the expression of SN...
Prognostic value of TMPRSS4 expression in patients with breast cancer.
Transmembrane protease, serine 4 (TMPRSS4), is a novel type II transmembrane serine protease that is highly expressed on the cell surface in pancreatic, thyroid, lung, and other cancer tissues, althou...
Breast cancer is the most common cancer in women worldwide. The disease remains a public health concern as recent evidence indicates that the breast cancer burden has increased mainly in developing an...
p73 gene shares structural and functional similarities to p53 and plays an important role in modulating cell cycle arrest and apoptosis. A common non-coding polymorphism of p73 G4C14-to-A4T14 (rs22739...
Accelerated hypofractionation (HF) using larger dose per fraction, delivered in fewer fractions over a shorter overall treatment time, is presently a consistent possibility for adjuvant whole breast r...
Prognostic value of proliferation markers expression in breast cancer.
In this study, immunohistochemical expression of five proliferation markers: Ki-67, aurora-A kinase, survivin, B-Myb and cyclin B1, was analyzed. Consecutive 215 tumor samples from breast cancer patie...
Clinical implications of CIP2A protein expression in breast cancer.
The aim of this work is to study the expression and regulatory effects of CIP2A protein in breast cancer and the correlation between CIP2A protein expression and the prognosis of breast cancer. The CI...
P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer.
Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has...
The breast cancer type 1 susceptibility gene (BRCA1) is a tumor suppressor gene, mutations or loss of which lead to genomic instability and breast cancer. BRCA1 protein is part of a large multi-protei...
News Articles
Enzym protective function: breast cancer advance that turns previous thinking on its head
Scientists at the University of East Anglia have made an advance in breast cancer research which shows how some enzymes released by cancerous cells could have a protective function. New research publi...
Background: Mitochondrial outer membrane permeabilization (MOMP) is a crucial step leading to apoptotic destruction of cancer cells. Bcl-2 family proteins delicately regulate mitochondrial outer membr...
The Canadian Breast Cancer Foundation - BC/Yukon Region is proud to award $300,000 in Breast Cancer Research Postgraduate Fellowships to five of the most qualified breast cancer research projects acro...
Dr. DeLange operated on both Mo and Sally of KOOL 105.5 FM’s “Mo & Sally Morning Show.” Palm Beach Gardens, FL (PRWEB) May 24, 2013 In a coup that surely made other Palm Beach plastic surge...
GIA announces the release of a comprehensive global report on Breast Pumps markets. Global market for Breast Pumps is projected to reach 7.3 million units by 2018, driven by increasing number of young...
Merrimack completes patient enrollment in Phase 2 breast cancer study
Merrimack Pharmaceuticals has completed patient enrollment in a Phase 2 study evaluating the efficacy of MM-121 in combination with exemestane compared to exemestane alone in breast cancer.
Breast cancer enzyme may slow tumour growth
"Cancer cell enzymes shown to act as 'good cops'," is the headline on the BBC News website. The BBC reports on laboratory research into an enzyme called MMP-8 and its effects on breast canc...
Reputation Impression Announces Sponsorship for Susan G. Komen for the Cure, San Diego
Reputation Impression, a Reputation Management and Marketing Company, is excited to announce its Silver Level Sponsorship for the Susan G. Komen, San Diego Race for the Cure. On S...
FDA grants Priority Review for Celgene pancreatic cancer treatment sNDA
The FDA has assigned a Priority Review designation to the sNDA for the use of Celgene’s ABRAXANE (paclitaxel protein-bound particles for injectable suspension) in combination with gemcitabine for th...
Events
None
Companies
TOPS Comprehensive Breast Center
OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and...
Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells...
More than 30 years ago, Nancy G. Brinker promised her dying sister, Suzy, she would do everything in her power to end breast cancer. Today, Susan G. Komen® works to end breast...
Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company...
Verastem, Inc. is a private biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. Cancer stem cells are an underly...
Nancy G. Brinker promised her dying sister, Suzy, she would do everything in her power to end breast cancer. Today, Susan G. Komen® works to end breast cancer in the U.S. and t...
Susan G. Komen for the Cure and Dallas Cowboys
Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the...
The WIN Consortium (www.winconsortium.org) is a joint initiative of Institut Gustave Roussy (France) and University of Texas - MD Anderson Cancer Center (USA) which brings togethe...
Cancer Be Glammed, LLC was founded by Lisa Lurie, a breast cancer survivor and Ellen Weiss Kander, who underwent chemotherapy for a rare blood disorder. They believe cancer can be...
Clinical Trials
Cell Lines From High-Risk Breast Tissue
Background: - Many risk factors for breast cancer have been identified, including family history, endocrine background, changes in breast tissue, cancer in one breast, radiation...
In this open-label multicenter trial patients with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (docetaxel followe...
89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition
HSP90 inhibition is a potentially new targeted drug modality in the treatment of HER2 positive, trastuzumab refractory breast cancer. Little is known about the pharmacodynamics of HSP90 in...
Background: - BRCA1 and BRCA2 gene mutations have been linked to a higher risk of developing breast cancer and other cancers, and may be associated with types of breast cancer that are mo...
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
Background: - Drugs given to treat cancer (chemotherapy) can weaken the human immune system. But it can also become weaker because of aging. Interleukin (IL)-7, a molecule produced natura...
RATIONALE: Aromatase inhibitors, such as letrozole, prevent the formation of estradiol, a female hormone. Giving letrozole together with goserelin, leuprolide, or surgery may be an effecti...
Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitax...
The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
Breast reconstruction is a common procedure with over 86,000 breast reconstruction procedures performed in the United States in 2009. This is a 1.5-fold increase since 2007. Of these breas...
BAY43-9006 - Phase II in Advanced Breast Cancer
The purpose of this study is to evaluate the anti-cancer activity and safety of BAY43-9006 (Sorafenib) in patients, who suffer from an advanced breast tumour, which has spread to other org...
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and urine from patients with or without breast cancer to study in the laboratory may help the study of cancer. PURPOSE: This re...
Videos
Breast Augmentation, liposuction and scar correction
http://beverlyhillsplasticsurgery.com (310) 271-6996 Follow Lindsey and her experience as she has a Breast Augmentation, liposuction and scar enhancement sur...
Medical and Biotech [MESH] Definitions
Infant Formula
Liquid formulations for the nutrition of INFANTS, useful for those with special needs or MILK HYPERSENSITIVITY or those whose mothers are unable to breastfeed (BREAST FEEDING).
Mammary Glands, Human
Glandular tissue in the BREAST of human that is under the influence of hormones such as ESTROGENS; PROGESTINS; and PROLACTIN. In WOMEN, after PARTURITION, the mammary glands secrete milk (MILK, HUMAN) for the nourishment of the young.
Breast Cyst
A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.
Fibroblast Growth Factor 8
A fibroblast growth factor that preferentially activates FIBROBLAST GROWTH FACTOR RECEPTOR 4. It was initially identified as an androgen-induced growth factor and plays a role in regulating growth of human BREAST NEOPLASMS and PROSTATIC NEOPLASMS.
Lactobacillus Reuteri
A species of gram-positive, rod-shaped LACTIC ACID bacteria found naturally in the human intestinal flora and BREAST MILK.
